Preconference • HPV Public Health Workshop • July 3-4, 2010
Print PDF

To view the Public Health Speaker Bios please click here!

July 2, 2010
5:00 PM -
9:00 PM
Registration

July 3, 2010 – Day 1
7:00 AM
Registration

8:15 AM
Welcome remarks by Steering Committee co-chairs

123Howard Njoo, Public Health Agency of Canada, Ottawa, ON, Canada



118Marc Steben, Institut national de santé publique du Québec, Montréal, QC, Canada

8:30 AM
Opening plenary - HPV: global perspectives
A global public health perspective on the challenges and opportunities for prevention and control of cervical cancer and HPV-related diseases.
Susan Wang, World Health Organization, Geneva, Switzerland


Screening Track
Scientific Committee [link]
Cytology-based screening has been very successful in reducing the incidence and mortality rates of cervical cancer in many countries but has also shown many limitations. Definitive association of certain HPV infections with cervical cancer has led to consider HPV DNA testing as a viable option for screening and there is mounting evidence now to support its efficacy in identifying high grade cervical lesions. In the context of this new screening paradigm, participants will compare screening strategies and discuss the challenges of implementing a new approach.

At the end of this track, participants will be able to:

  • Define a systematic approach to selecting the most appropriate screening technology in a given environment;
  • Discuss factors associated with the successful implementation of a new screening policy.
9:00 AM
Overview of the current situation

115Comparison of cytology and HPV tests' clinical effectiveness
Marie-Hélène Mayrand, Centre de recherche du Centre hospitalier de l'Université de Montréal and Institut national de santé publique du Québec, Montréal, QC, Canada


125Review of cost-effectiveness studies
Jane J. Kim, Harvard School of Public Health, Boston, MA, USA



143Impact of vaccination on screening test performance
Salaheddin M. Mahmud, University of Manitoba, Winnipeg, MB, Canada



Questions from the audience
9:40 AM
Panel - HPV screening experiences
Moderator: Meg McLachlin, University of Western Ontario, London, ON, Canada

0049_Kitchener_LoResUnited Kingdom
Henry Kitchener, University of Manchester, Manchester, United Kingdom



0113_Anttila_LoResFinland
Ahti Anttila, Finnish Cancer Registry, Helsinki, Finland



127Canada - British Columbia
Dirk van Niekerk, Cervical Cancer Screening Program, Vancouver, BC, Canada




120United States
Mona Saraiya, Centers for Disease Control and Prevention, Atlanta, GA, USA

 

Questions from the audience
10:30 AM
Break
11:00 AM
Interactive session: scenarios
Participants will move into small groups. The purpose of the session will be to share experience and knowledge to address issues related to implementing new screening technologies. Participants should apply their own experience as well as any knowledge or lessons learned from the earlier panel discussion. A facilitator and HPV expert will animate the discussion around one of the pre-selected theme:
• Clinical guidelines;
• Training & manpower adaptation;
• Monitoring and evaluation;
• Communication with the population.
12:00 PM
The future of screening

14A risk-based model for integrating new technologies, including HPV vaccination and new biomarkers, into cervical cancer prevention programs
Philip Castle, National Cancer Institute, Bethesda, MD, USA


128Concluding remarks on Screening Track
Meg McLachlin, University of Western Ontario, London, ON, Canada
12:30 PM
Lunch


Vaccine Track
Scientific Committee [link]
The purpose of this track is to familiarize participants with new developments and information on HPV vaccines and to provide them with a better understanding of the considerations and issues to be address when deciding about HPV vaccination programs implementation and optimization. Australian, Canadian, UK and the US experiences with HPV vaccine will be shared with participants. Different approaches and options for immunization program rollout will be discussed.

At the end of this track, participants will be able to:

  • Summarize the essential information regarding immunogenicity, efficacy, and safety of HPV vaccines;
  • Apply lessons learned to develop or improve HPV immunization programs in their jurisdictions.

1:45 PM
Overview of new information on the vaccine
129Shelly McNeil, Canadian Center for Vaccinology, Nova Scotia, Canada
2:05 PM
Panel - Experiences developing and implementing HPV immunization programs

130Canada | NACI-CIC process for program implementation & Québec | Extended vaccination schedule
Shelley Deeks, Ontario Agency for Health Protection and Promotion, Toronto, ON, Canada



19United Kingdom
Jack Cuzick, Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, London, United Kingdom

0132_Brotherton_LoResAustralia
Julia Brotherton, National HPV Vaccination Program Register, East Melbourne, Australia

 

United States
Lauri Markowitz, Centers for Disease Control and Prevention, Atlanta, GA, USA

Questions from the audience
3:15 PM
Break

3:45 PM
Interactive session: scenarios

Participants will work in small groups. The purpose of the session will be to share experience and knowledge to address issues related to HPV immunization program development and implementation. Small groups will allow participants to discuss lessons learned and apply this information to real life scenarios.

4:30 PM
Summary presentation

Highlights from discussions will be shared within each break-out room, to be followed by concluding remarks on Vaccine Track.